Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 26, Issue 14, 2013, Pages 1359-1370

  Stampalija, Tamara ^a,b,c   Chaiworapongsa, Tinnakorn ^a,b   Romero, Roberto ^a   Chaemsaithong, Piya ^a,b   Korzeniewski, Steven J ^a,b   Schwartz, Alyse G ^a,b   Ferrazzi, Enrico M ^c   Dong, Zhong ^a   Hassan, Sonia S ^a,b  

^a HUTZEL HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Biomarker; Interleukin 33; Pregnancy; Sflt 1; Th2 immune response; VEGFR 1

Indexed keywords

BINDING PROTEIN; ENDOGLIN; INTERLEUKIN 33; PLACENTAL GROWTH FACTOR; PROTEIN SOLUBLE ST2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL PLASMA; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; INTERLEUKINS; LASER-DOPPLER FLOWMETRY; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; SOLUBILITY; UMBILICAL ARTERIES; UTERINE ARTERY; YOUNG ADULT;

EID: 84882438122     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2013.784256     Document Type: Article

References (178)

1. Romero R. Prenatal medicine: The child is the father of the man. 1996. J Matern Fetal Neonatal Med 2009;22:636-9
2. Di Renzo GC. The great obstetrical syndromes. J Matern Fetal Neonatal Med 2009;22:633-5
3. Romero R, Lockwood C, Oyarzun E, Hobbins JC. Toxemia: New concepts in an old disease. Semin Perinatol 1988;12:302-23
4. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-4 (Pubitemid 40807500)
5. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancyrelated mortality in the United States, 1998 to 2005. Obstet Gynecol 2010;116:1302-9
6. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy 2003;22:203-12 (Pubitemid 37521372)
7. Jelin AC, Cheng YW, Shaffer BL, et al. Early-onset preeclampsia and neonatal outcomes. J Matern Fetal Neonatal Med 2010;23: 389-92
8. Schneider S, Freerksen N, Maul H, et al. Risk groups and maternalneonatal complications of preeclampsia-current results from the national German Perinatal Quality Registry. J Perinat Med 2011;39: 257-65
9. Brosens IA. Morphological changes in the utero-placental bed in pregnancy hypertension. Clin Obstet Gynaecol 1977;4:573-93 (Pubitemid 8234457)
10. Brosens JJ, Pijnenborg R, Brosens IA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: A review of the literature. Am J Obstet Gynecol 2002;187:1416-23 (Pubitemid 35397496)
11. Pijnenborg R, Anthony J, Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991;98:648-55
12. Robertson WB, Brosens I, Dixon G. Maternal uterine vascular lesions in the hypertensive complications of pregnancy. Perspect Nephrol Hypertens 1976;5:115-27
13. Brosens I, Pijnenborg R, Vercruysse L, Romero R. The ''Great Obstetrical Syndromes'' are associated with disorders of deep placentation. Am J Obstet Gynecol 2011;204:193-201
14. George EM, Granger JP. Linking placental ischemia and hypertension in preeclampsia: Role of endothelin 1. Hypertension 2012;60: 507-11
15. Ogge G, Chaiworapongsa T, Romero R, et al. Placental lesions associated with maternal underperfusion are more frequent in earlyonset than in late-onset preeclampsia. J Perinat Med 2011;39:641-52
16. Gilbert JS, Ryan MJ, LaMarca BB, et al. Pathophysiology of hypertension during preeclampsia: Linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008;294: H541-50
17. Cindrova-Davies T. Gabor than Award lecture 2008: Pre-eclampsia - from placental oxidative stress to maternal endothelial dysfunction. Placenta 2009;30:S55-65
18. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 1999;222:222-35
19. Vaughan JE, Walsh SW. Oxidative stress reproduces placental abnormalities of preeclampsia. Hypertens Pregnancy 2002;21: 205-23 (Pubitemid 36090319)
20. Myatt L, Kossenjans W, Sahay R, et al. Oxidative stress causes vascular dysfunction in the placenta. J Matern Fetal Med 2000;9: 79-82 (Pubitemid 30176218)
21. Zhou X, Zhang GY, Wang J, et al. A novel bridge between oxidative stress and immunity: The interaction between hydrogen peroxide and human leukocyte antigen G in placental trophoblasts during preeclampsia. Am J Obstet Gynecol 2012;206:447 e447-16
22. Burton GJ, Yung HW, Cindrova-Davies T, Charnock-Jones DS. Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia. Placenta 2009;30:S43-8
23. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998;179:80-6 (Pubitemid 28394477)
24. Redman CW, Sacks GP, Sargent IL. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506 (Pubitemid 29093892)
25. Gervasi MT, Chaiworapongsa T, Pacora P, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001;185:792-7 (Pubitemid 32980513)
26. Friedman SA, Schiff E, Emeis JJ, et al. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 1995;172:202-3
27. Lyall F, Greer IA. The vascular endothelium in normal pregnancy and pre-eclampsia. Rev Reprod 1996;1:107-16 (Pubitemid 126664713)
28. Roberts JM, Hubel CA. The two stage model of preeclampsia: Variations on the theme. Placenta 2009;30:S32-7
29. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-4 (Pubitemid 20007682)
30. Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991;4:700-8
31. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:5-15 (Pubitemid 28285299)
32. Taylor RN, de Groot CJ, Cho YK, Lim KH. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:17-31 (Pubitemid 28285300)
33. Chaiworapongsa T, Romero R, Yoshimatsu J, et al. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J Matern Fetal Neonatal Med 2002;12:19-27 (Pubitemid 34848424)
34. Petrozella L, Mahendroo M, Timmons B, et al. Endothelial microparticles and the antiangiogenic state in preeclampsia and the postpartum period. Am J Obstet Gynecol 2012;207: 140.e120-46
35. Vitoratos N, Economou E, Iavazzo C, et al. Maternal serum levels of TNF-alpha and IL-6 long after delivery in preeclamptic and normotensive pregnant women. Mediators Inflamm 2010;2010: 908649
36. Sharma A, Satyam A, Sharma JB. Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol 2007;58:21-30 (Pubitemid 46939024)
37. Szarka A, Rigo Jr J, Lazar L, et al. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010;11:59
38. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997;37:240-9 (Pubitemid 27149786)
39. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998;40:102-11
40. Xiao JP, Yin YX, Gao YF, et al. The increased maternal serum levels of IL-6 are associated with the severity and onset of preeclampsia. Cytokine 2012;60:856-60
41. Jonsson Y, Ruber M, Matthiesen L, et al. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J Reprod Immunol 2006;70:83-91
42. Freeman DJ, McManus F, Brown EA, et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 2004;44:708-14 (Pubitemid 39435242)
43. Borekci B, Aksoy H, Al RA, et al. Maternal serum interleukin-10, interleukin-2 and interleukin-6 in pre-eclampsia and eclampsia. Am J Reprod Immunol 2007;58:56-64 (Pubitemid 46939028)
44. Kucuk M, Sezer SD, Yenisey C, et al. Comparison of interleukin-6 levels in maternal and umbilical cord blood in early- and late-onset preeclampsia. Gynecol Endocrinol 2012;28:640-3
45. Piering WF, Garancis JG, Becker CG, et al. Preeclampsia related to a functioning extrauterine placenta: Report of a case and 25-year follow-up. Am J Kidney Dis 1993;21:310-3 (Pubitemid 23100345)
46. Kanter D, Lindheimer MD, Wang E, et al. Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol 2010;202:184.e181-5
47. Hou JL, Wan XR, Xiang Y, et al. Changes of clinical features in hydatidiform mole: Analysis of 113 cases. J Reprod Med 2008;53: 629-33
48. Speroff L. Toxemia of pregnancy. Mechanism and therapeutic management. Am J Cardiol 1973;32:582-91
49. Toxaemias of pregnancy. General considerations. Q Med Rev 1968;18:1-36
50. Morrison JC, Whybrew DW, Wiser WL, et al. Laboratory characteristics in toxemia. Obstet Gynecol 1972;39:866-72
51. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143-8 (Pubitemid 37521365)
52. Egbor M, Ansari T, Morris N, et al. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG 2006;113:580-9
53. Moldenhauer JS, Stanek J, Warshak C, et al. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003;189:1173-7 (Pubitemid 37373917)
54. Romero R, Vizoso J, Emamian M, et al. Clinical significance of liver dysfunction in pregnancy-induced hypertension. Am J Perinatol 1988;5:146-51
55. Romero R, Mazor M, Lockwood CJ, et al. Clinical significance, prevalence, and natural history of thrombocytopenia in pregnancyinduced hypertension. Am J Perinatol 1989;6:32-8 (Pubitemid 19053821)
56. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365:785-99
57. Tuffnell DJ, Jankowicz D, Lindow SW, et al. Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. BJOG 2005;112: 875-80 (Pubitemid 40896951)
58. Haddad B, Barton JR, Livingston JC, et al. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: Onset at5or 28.0 weeks' gestation. Am J Obstet Gynecol 2000;183:1475-9 (Pubitemid 32061210)
59. Langenveld J, Jansen S, van der Post J, et al. Recurrence risk of a delivery before 34 weeks of pregnancy due to an early onset hypertensive disorder: A systematic review. Am J Perinatol 2010;27: 565-71
60. Sep S, Verbeek J, Koek G, et al. Clinical differences between earlyonset HELLP syndrome and early-onset preeclampsia during pregnancy and at least 6 months postpartum. Am J Obstet Gynecol 2010;202:271.e271-5
61. Sibai BM. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol 2006;30:16-9
62. Ales KL, Charlson ME. Epidemiology of preeclampsia and eclampsia. Am J Obstet Gynecol 1991;165:238
63. Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: The elusive preeclampsia factor discovered? J Clin Invest 2003;111: 600-2 (Pubitemid 36278577)
64. Bujold E, Romero R, Chaiworapongsa T, et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonatal Med 2005;18:9-16 (Pubitemid 41224357)
65. Crispi F, Dominguez C, Llurba E, et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006;195: 201-7 (Pubitemid 43927524)
66. Chaiworapongsa T, Romero R, Gotsch F, et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med 2008;21:41-52
67. Chaiworapongsa T, Romero R, Tarca AL, et al. A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. Am J Obstet Gynecol 2010;202: 550.e551-10
68. Benton SJ, Hu Y, Xie F, et al. Angiogenic factors as diagnostic tests for preeclampsia: A performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011;205: 469.e461-8
69. Ghosh SK, Raheja S, Tuli A, et al. Serum PLGF as a potential biomarker for predicting the onset of preeclampsia. Arch Gynecol Obstet 2012;285:417-22
70. Hagmann H, Thadhani R, Benzing T, et al. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 2012;58:837-45
71. Verlohren S, Stepan H, Dechend R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci (Lond) 2012;122:43-52
72. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005;46:1077-85 (Pubitemid 41533005)
73. Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012;25:2651-7
74. Bahado-Singh RO, Akolekar R, Mandal R, et al. Metabolomics and first-trimester prediction of early-onset preeclampsia. J Matern Fetal Neonatal Med 2012;25:1840-7
75. Chaiworapongsa T, Romero R, Savasan ZA, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24:1187-207
76. Mazaki-Tovi S, Vaisbuch E, Romero R, et al. Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate. J Matern Fetal Neonatal Med 2010;23:1119-28
77. Sibai B, Romero R, Klebanoff MA, et al. Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia. Am J Obstet Gynecol 2009;200:630.e631-8
78. Romero R, Kusanovic JP, Than NG, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008;199:122.e1-11
79. Serin IS, Ozcelik B, Basbug M, et al. Predictive value of tumor necrosis factor alpha (TNF-alpha) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2002;100:143-5 (Pubitemid 34030575)
80. Kronborg CS, Gjedsted J, Vittinghus E, et al. Longitudinal measurement of cytokines in pre-eclamptic and normotensive pregnancies. Acta Obstet Gynecol Scand 2011;90:791-6
81. Bodova KB, Biringer K, Dokus K, et al. Fibronectin, plasminogen activator inhibitor type 1 (PAI-1) and uterine artery Doppler velocimetry as markers of preeclampsia. Dis Markers 2011;30: 191-6
82. Dusse LM, Carvalho MG, Getliffe K, et al. Increased circulating thrombomodulin levels in pre-eclampsia. Clin Chim Acta 2008; 387:168-71 (Pubitemid 350050927)
83. Boffa MC, Valsecchi L, Fausto A, et al. Predictive value of plasma thrombomodulin in preeclampsia and gestational hypertension. Thromb Haemost 1998;79:1092-5 (Pubitemid 28297152)
84. Shaarawy M, Didy HE. Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. Int J Gynaecol Obstet 1996;55:135-9 (Pubitemid 26383740)
85. Hsu CD, Iriye B, Johnson TR, et al. Elevated circulating thrombomodulin in severe preeclampsia. Am J Obstet Gynecol 1993;169:148-9 (Pubitemid 23223948)
86. Minakami H, Takahashi T, Izumi A, Tamada T. Increased levels of plasma thrombomodulin in preeclampsia. Gynecol Obstet Invest 1993;36:208-10 (Pubitemid 23343698)
87. Hsu CD, Copel JA, Hong SF, Chan DW. Thrombomodulin levels in preeclampsia, gestational hypertension, and chronic hypertension. Obstet Gynecol 1995;86:897-9 (Pubitemid 27331480)
88. Bontis J, Vavilis D, Agorastos T, et al. Maternal plasma level of thrombomodulin is increased in mild preeclampsia. Eur J Obstet Gynecol Reprod Biol 1995;60:139-41
89. Thilaganathan B, Wormald B, Zanardini C, et al. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol 2010;115: 1233-8
90. Meads CA, Cnossen JS, Meher S, et al. Methods of prediction and prevention of pre-eclampsia: Systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008;12:iii-iv, 1-270
91. Mei-Dan E, Wiznitzer A, Sergienko R, et al. Prediction of preeclampsia: Liver function tests during the first 20 gestational weeks. J Matern Fetal Neonatal Med 2013;26:250-3
92. Torry DS, Wang HS, Wang TH, et al. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998;179:1539-44 (Pubitemid 29028397)
93. Tidwell SC, Ho HN, Chiu WH, et al. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001;184:1267-72 (Pubitemid 32434285)
94. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58 (Pubitemid 36278583)
95. Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88: 2348-51 (Pubitemid 36549917)
96. Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-82 (Pubitemid 36135616)
97. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555-63 (Pubitemid 37452769)
98. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541-7
99. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642-9 (Pubitemid 43865232)
100. Reuvekamp A, Velsing-Aarts FV, Poulina IE, et al. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999;106: 1019-22 (Pubitemid 29457082)
101. Garovic VD. The role of angiogenic factors in the prediction and diagnosis of preeclampsia superimposed on chronic hypertension. Hypertension 2012;59:555-7
102. Molvarec A, Szarka A, Walentin S, et al. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010;33:892-8
103. Staff AC, Braekke K, Johnsen GM, et al. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol 2007;197: 176.e171-6
104. Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008;21:25-40
105. Crispi F, Llurba E, Dominguez C, et al. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008;31:303-9
106. Asvold BO, Vatten LJ, Romundstad PR, et al. Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. Am J Epidemiol 2011;173:630-9
107. Gourvas V, Dalpa E, Konstantinidou A, et al. Angiogenic factors in placentas from pregnancies complicated by fetal growth restriction (review). Mol Med Report 2012;6:23-7
108. Espinoza J, Chaiworapongsa T, Romero R, et al. Unexplained fetal death: Another anti-angiogenic state. J Matern Fetal Neonatal Med 2007;20:495-507 (Pubitemid 47221572)
109. Chaiworapongsa T, Kusanovic JP, Savasan ZA, et al. Fetal death: A condition with a dissociation in the concentrations of soluble vascular endothelial growth factor receptor-2 between the maternal and fetal compartments. J Matern Fetal Neonatal Med 2010; 23:960-72
110. Chaiworapongsa T, Romero R, Kusanovic JP, et al. Unexplained fetal death is associated with increased concentrations of antiangiogenic factors in amniotic fluid. J Matern Fetal Neonatal Med 2010;23:794-805
111. Bixel K, Silasi M, Zelop CM, et al. Placental origins of angiogenic dysfunction in mirror syndrome. Hypertens Pregnancy 2012;31: 211-17
112. Espinoza J, Romero R, Nien JK, et al. A role of the antiangiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). J Matern Fetal Neonatal Med 2006;19: 607-13 (Pubitemid 44804787)
113. Koga K, Osuga Y, Tajima T, et al. Elevated serum soluble fmslike tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 2010;94:305-8
114. Kusanovic JP, Romero R, Espinoza J, et al. Twin-to-twin transfusion syndrome: An antiangiogenic state? Am J Obstet Gynecol 2008;198:382.e381-8
115. Llurba E, Marsal G, Sanchez O, et al. Angiogenic and antiangiogenic factors before and after resolution of maternal mirror syndrome. Ultrasound Obstet Gynecol 2012;40:367-9
116. Rana S, Venkatesha S, DePaepe M, et al. Cytomegalovirusinduced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol 2007;109: 549-52 (Pubitemid 46146857)
117. Chaiworapongsa T, Romero R, Tarca A, et al. A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: Evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. J Matern Fetal Neonatal Med 2009;22:1122-39
118. Romero R, Chaiworapongsa T, Erez O, et al. An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: Results of a longitudinal study. J Matern Fetal Neonatal Med 2010;23:1384-99
119. Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3-18 (Pubitemid 40515938)
120. Moore Simas TA, Crawford SL, Solitro MJ, et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007;197:244.e241-8
121. Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008;21:279-87 (Pubitemid 351652513)
122. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor- 1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23
123. Unal ER, Robinson CJ, Johnson DD, Chang EY. Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. Am J Obstet Gynecol 2007;197:211.e211-14
124. Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: A systematic review. Obstet Gynecol 2007;109:168-80 (Pubitemid 46035522)
125. Park CW, Park JS, Shim SS, et al. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 2005;193:984-9
126. Rana S, Hacker MR, Modest AM, et al. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension 2012;60:451-8
127. Rana S, Cerdeira AS, Wenger J, et al. Plasma Concentrations of Soluble Endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One 2012;7:e48259
128. Wikstrom AK, Larsson A, Eriksson UJ, et al. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007;109:1368-74 (Pubitemid 46869876)
129. Robinson CJ, Johnson DD, Chang EY, et al. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006;195:255-9 (Pubitemid 43927517)
130. Pedrosa AC, Matias A. Screening for pre-eclampsia: A systematic review of tests combining uterine artery Doppler with other markers. J Perinat Med 2011;39:619-35
131. Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22: 1021-38
132. Granne I, Southcombe JH, Snider JV, et al. ST2 and IL-33 in pregnancy and pre-eclampsia. PLoS One 2011;6:e24463
133. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989;258:301-4 (Pubitemid 20001074)
134. Tominaga S, Inazawa J, Tsuji S. Assignment of the human ST2 gene to chromosome 2 at q11.2. Hum Genet 1996;97:561-3 (Pubitemid 26112018)
135. Werenskiold AK, Hoffmann S, Klemenz R. Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol 1989;9:5207-14 (Pubitemid 19275992)
136. Klemenz R, Hoffmann S, Werenskiold AK. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci U S A 1989;86:5708-12 (Pubitemid 19217524)
137. Meisel C, Bonhagen K, Lohning M, et al. Regulation and function of T1/ST2 expression on CD4 T cells: Induction of type 2 cytokine production by T1/ST2 cross-linking. J Immunol 2001; 166:3143-50 (Pubitemid 33117311)
138. Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998;95: 6930-5 (Pubitemid 28278084)
139. Trajkovic V, Sweet MJ, Xu D. T1/ST2-an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev 2004;15:87-95 (Pubitemid 38523333)
140. Yanagisawa K, Naito Y, Kuroiwa K, et al. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myelomaderived RPMI8226 cells. J Biochem 1997;121:95-103 (Pubitemid 27068281)
141. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1- like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-90 (Pubitemid 41587888)
142. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007;179:2051-4
143. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009;113:1526-34
144. Bourgeois E, Van LP, Samson M, et al. The pro-Th2 cytokine IL- 33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009;39:1046-55
145. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007;282:26369-80 (Pubitemid 47443815)
146. Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008;52:2166-74
147. Topping V, Romero R, Than NG, et al. Interleukin-33 in the Human Placenta. J Matern Fetal Neonatal Med 2013;26:327-38
148. Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009;179:772-81
149. Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004;30:1468-73 (Pubitemid 38951733)
150. Hoogerwerf JJ, Tanck MW, van Zoelen MA, et al. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 2010;36:630-7
151. Mildner M, Storka A, Lichtenauer M, et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 2010;87:769-77
152. Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with STelevation myocardial infarction. Circulation 2008;117:1936-44 (Pubitemid 351543469)
153. Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-6 (Pubitemid 36222600)
154. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-49 (Pubitemid 46871338)
155. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205:339-46 (Pubitemid 351281600)
156. Lecart S, Lecointe N, Subramaniam A, et al. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol 2002;32:2979-87 (Pubitemid 35238191)
157. Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010;107:8017-22
158. Kurokawa M, Matsukura S, Kawaguchi M, et al. Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts. Int Arch Allergy Immunol 2011;155:12-20
159. Oshikawa K, Kuroiwa K, Tokunaga T, et al. Acute eosinophilic pneumonia with increased soluble ST2 in serum and bronchoalveolar lavage fluid. Respir Med 2001;95:532-3 (Pubitemid 32622009)
160. Marzi M, Vigano A, Trabattoni D, et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996;106: 127-33 (Pubitemid 26329391)
161. Saito S, Sakai M, Sasaki Y, et al. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp Immunol 1999;117:550-5 (Pubitemid 29398304)
162. Alexander GR, Himes JH, Kaufman RB, et al. United States national reference for fetal growth. Obstet Gynecol 1966;87: 163-8
163. Sibai BM, Ewell M, Levine RJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1997;177:1003-10 (Pubitemid 27525346)
164. Chaiworapongsa T, Romero R, Kusanovic JP, et al. Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol 2010;35:155-62
165. Kurmanavicius J, Florio I, Wisser J, et al. Reference resistance indices of the umbilical, fetal middle cerebral and uterine arteries at 24-42 weeks of gestation. Ultrasound Obstet Gynecol 1997;10: 112-20 (Pubitemid 27412251)
166. Arduini D, Rizzo G. Normal values of Pulsatility Index from fetal vessels: A cross-sectional study on 1556 healthy fetuses. J Perinat Med 1990;18:165-72 (Pubitemid 20217555)
167. Trudinger BJ, Cook CM, Giles WB, et al. Fetal umbilical artery velocity waveforms and subsequent neonatal outcome. Br J Obstet Gynaecol 1991;98:378-84
168. Luppi P, Tse H, Lain KY, et al. Preeclampsia activates circulating immune cells with engagement of the NF-kappaB pathway. Am J Reprod Immunol 2006;56:135-44
169. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006;11:309-16 (Pubitemid 44038703)
170. Mihu D, Sabau L, Costin N, et al. Implications of maternal systemic oxidative stress in normal pregnancy and in pregnancy complicated by preeclampsia. J Matern Fetal Neonatal Med 2012;25:944-51
171. Borzychowski AM, Croy BA, Chan WL, et al. Changes in systemic type 1 and type 2 immunity in normal pregnancy and pre-eclampsia may be mediated by natural killer cells. Eur J Immunol 2005;35:3054-63 (Pubitemid 41555101)
172. Borghi C, Esposti DD, Immordino V, et al. Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. Am J Obstet Gynecol 2000;183: 140-7 (Pubitemid 30626041)
173. Sala C, Campise M, Ambroso G, et al. Atrial natriuretic peptide and hemodynamic changes during normal human pregnancy. Hypertension 1995;25:631-6
174. Castro LC, Hobel CJ, Gornbein J. Plasma levels of atrial natriuretic peptide in normal and hypertensive pregnancies: A meta-analysis. Am J Obstet Gynecol 1994;171:1642-51
175. Vanderheyden M, Goethals M, Verstreken S, et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 2004;44:2349-54 (Pubitemid 39647609)
176. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106: 2961-6 (Pubitemid 35424749)
177. Mayhew TM, Ohadike C, Baker PN, et al. Stereological investigation of placental morphology in pregnancies complicated by pre-eclampsia with and without intrauterine growth restriction. Placenta 2003;24:219-26 (Pubitemid 37184718)
178. Manetti M, Ibba-Manneschi L, Liakouli V, et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 2010;69:598-605 Development